Saracatinib (AZD0530) Is a Potent Modulator of ABCB1-mediated Multidrug Resistance in Vitro and in Vivo

Saracatinib, a highly selective, dual Src/Abl kinase inhibitor, is currently in a phase II clinical trial for the treatment of ovarian cancer. In this study, we investigated the effect of saracatinib on the reversal of multidrug resistance (MDR) induced by ATP-binding cassette (ABC) transporters in...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Liu, Ke-jun, He, Jie-hua, Su, Xiao-dong, Sim, Hong-May, Xie, Jing-dun, Chen, Xing-gui, Wang, Fang, Liang, Yong-ju, Singh, Satyakam, Sodani, Kamlesh, Talele, Tanaji T., Ambudkar, Suresh V., Chen, Zhe-Sheng, Wu, Hai-Ying, Fu, Li-wu
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2012
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3459133/
https://ncbi.nlm.nih.gov/pubmed/22623106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.27649
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg